Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Given this risk, we thought we'd take a look at whether Skye Bioscience (NASDAQ:SKYE) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate ...

About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes.

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several ...

Skye preparing to start Phase 2a glaucoma clinical trial in Q3San Diego, California-- (Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTC ...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Mar. 20, 2025 4:01 PM ET Skye Bioscience, Inc. (SKYE) ...

Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report)’s stock price rose 24% on Thursday . The company traded as high as $1.81 and last traded at $2.15. Approximately 320,782 shares traded ...

Skye Bioscience, Inc. announced that it has granted stock options for 56,000 shares of its common stock to two new non-executive employees as part of its 2024 Inducement Equity Incentive Plan, in ...

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation ...